MHRAsafety guidance83% confidence
Decision: Advertising investigations: May 2026
Source: MHRA
Why This Matters
Why this matters: sets a safety guidance precedent in the same sub-indication (immunology) as Roche.
Regulatory Analysis
Decisions made by MHRA on adverts reported to have breached the legislation on advertising medicines.
Supporting Context
- Therapeutic area
- Oncology · Diagnostics and Multiple Sclerosis · BTK Inhibitor
- Sub-indication
- Immunology
Related signal: Roche Reports Strong Q1 2026 Sales Growth Driven by Innovative Medicines and Diagnostics